This Biotech’s Proprietary Platform Could Unlock Its Next Growth Phase
Baird Equity Asset Management recently released its "Small/Mid Cap Growth Strategy" second-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Ascendis Pharma A/S (ASND)
This company is not actively trading or the ticker does belong to another company in our database now. The symbol (ASND) is currently associated with the following stock: Ascendis Pharma A/S (ASND)
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 0 | $0 | 0% | ||
| 2. | 0 | $0 | 0% | ||
| 3. | 0 | $0 | 0% | ||
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,600 | $592,358 | 0.01% | |
| 2. | 45 | $10,252 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% |
News See All
Ascendis Pharma (ASND) Authorizes $400M Share Buyback
On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares.
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?
Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following...
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
BioMarin Pharmaceutical Inc.
Ascendis Pharma Stock (ASND) Soars 7% on a Settlement with BioMarin Pharmaceutical (BMRN)
Ascendis Pharma stock rallied 7% on Monday after the company reached a global settlement and license deal with BioMarin Pharmaceutical.
Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine
On August 13, Ascendis Pharma (NASDAQ:ASND) reported second-quarter results that showed how far its rare disease portfolio has come.
Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its "Artisan Small Cap Fund". A copy of the letter can be downloaded here.
10 Most Profitable Growth Stocks to Buy
In this article, we will discuss the 10 Most Profitable Growth Stocks to Buy.
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2026 Earnings Call Transcript May 7, 2026Ascendis Pharma A/S beats earnings expectations. Reported EPS is $0.32, expectations were $0.21.
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
In this article, we discuss the Billionaire Joe Edelman's Stock Picks with Huge Upside Potential.
Hedge Fund Resource Center